Biricodar

Biricodar
Clinical data
ATC code	none;
Identifiers
	IUPAC name 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;
CAS Number	174254-13-8 ;
PubChem CID	3037617;
ChemSpider	2301309 ;
UNII	9WQP0L619L;
ChEMBL	ChEMBL350775 ;
CompTox Dashboard (EPA)	DTXSID50893944 ;
Chemical and physical data
Formula	C34H41N3O7
Molar mass	603.716 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C(=O)c1cc(OC)c(OC)c(OC)c1)N4[C@H](C(=O)OC(CCCc2cccnc2)CCCc3cccnc3)CCCC4;
	InChI InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1 ; Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N ;
	(verify)

Biricodar or incel (INN, codename VX-710) was a pharmaceutical drug under development by Vertex Pharmaceuticals to help treat ovarian cancer patients, that never reached the market.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.